Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Nonsquamous Nonsmall Cell Neoplasm of Lung

Intergroupe Francophone de Cancerologie ThoraciqueSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Nonsquamous Nonsmall Cell Neoplasm of Lung cohort.

Asset / SponsorPhaseRating
Carboplatin
Arcus Biosciences, Inc.
Phase 2BB
(+)-VINCRISTINE
Intergroupe Francophone de Cancerologie Thoracique
Phase 2B
Irinotecan
Intergroupe Francophone de Cancerologie Thoracique
Phase 2B
Demcizumab
OncoMed Pharmaceuticals, Inc.
Phase 2B
Metformin
Beth Israel Medical Center
Phase 2CCC

View all 20 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →